Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: In glaucoma and ocular hypertension

Drugs and Aging

Volumn 23, Issue 9, 2006, Pages 753-761

  Frampton, James E ^a,b  

^a Wolters Kluwer Health   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; TIMOLOL;

ALLERGIC CONJUNCTIVITIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TOLERABILITY; EYE PAIN; FATIGUE; GLAUCOMA; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; OCULAR PRURITUS; PRIORITY JOURNAL; REVIEW; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUINOXALINES; TIMOLOL; TREATMENT OUTCOME;

EID: 33749553050     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623090-00005     Document Type: Review

References (39)

1. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999; 60: 99-108
2. The Merck Manual. Section 8. Ophthalmological Disorders. Chapter 100. Glaucoma [online]. Available from URL: http://www.merck.com/mrkshared/mmanual/ home.jsp [Accessed 2006 Aug 10]
3. Rouland J-F, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension. Implications for patient management: a review. Drugs Aging 2005; 22 (4): 315-21
4. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002 Nov; 11 (11 Suppl.): 16-24
5. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004; 15: 119-26
6. The Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2006 Aug 10]
7. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15 (2): 132-5
8. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22 (1): 1-21
9. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001 Apr; 23 (4): 604-19
10. Stewart WC. Combination therapy: is the whole greater? Rev Ophthalmol 2005; 12 (6) [online]. Available from URL: http://www.revophth.com [Accessed 2006 Sep 28]
11. Allergan Ltd. Combigan eye drops, solution. Summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2006 Aug 10]
12. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995 Dec; 113 (12): 1514-7
13. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res 2004 Mar; 78 (3): 639-51
14. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol 2001 Apr; 119 (4): 492-5
15. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104 (1): 131-6
16. Carlsson AM, Chauhan BC, Lee A, et al. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 1999; 128: 697-701
17. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol 1998 Dec; 116: 1591-4
18. Costagliola C, Parmeggiani F, Ciancaglini M, et al. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica 2003 Jan 28; 217 (1): 39-44
19. Liu CJ, Ko YC, Cheng CY, et al. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol 2002 Nov; 86 (11): 1236-9
20. Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005 Oct; 89 (10): 1293-7
21. Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand 2003 Oct; 81 (5): 474-9
22. Galassi F, Sodi A, Renieri G, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica 2002 Mar; 216 (2): 123-8
23. Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998 Mar; 12: 225-41
24. Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002 Jun; 80 (3): 277-81
25. Korte J-M, Kailaa T, Matti Saari K. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 430-5
26. Heel RC, Brogden RN, Speight TM, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17: 38-55
27. Data on file, Allergan I, 2006
28. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2006; 124: 1-9
29. Goni FJ, Brimonidine/Timolol Fixed Combination Study Group. 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005 Sep 31; 15 (No. 5): 581-90
30. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005 Aug; 21 (4): 337-48
31. Buchholz P, Poulsen PB, Walt JG. A cost-minimization analysis of Combigan (brimonidine/timolol, fixed combination) in the treatment of primary open angle glaucoma in Europe [abstract plus poster presented at the 6th International Symposium on Ocular Pharmacology and Therapeutics; 2006 Mar 30-Apr 2; Berlin] [online]. Available from URL: http://www.kenes.com/isopt2006/ [Accessed 2006 Sep]
32. Nixon DR. Evaluation of the safety and efficacy of brimonidine tartrate-timolol maleate ophthalmic solution (Combigan®) and dorzolamide hydrochloride-timolol maleate ophthalmic solution (Cosopt®) in patients with open-angle glaucoma or ocular hypertension [abstract no. E-453-B188 plus poster presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Ft Lauderdale (FL)]. Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http://www.iovs.org [Accessed 2006 Sep]
33. Arcieri ES, Pereira ACA, Andreo EGV, et al. Fixed combination brimonidine-timolol (Combigan®) versus fixed combination dorzolamide-timolol (Cosopt®) each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension [abstract no. E-434-B169]. Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http://www.iovs.org [Accessed 2006 Sep]
34. Crichton ACS. Timolol/brimonidine combination therapy in glaucoma management. Clin Surg Ophthalmol 2005; 23 (10): 356-9
35. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003; 110: 615-24
36. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004; 13: 149-57
37. Ventura MP, Saheb NE, Solari HP, et al. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005; 30 (3): 251-4
38. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41 (Suppl. 1): 27-37
39. Motolko MA, Crichton A. A comparison of allergy rates in glaucoma patients receiving brimonidine monotherapy versus fixed combination brimonidine/timolol. Presented at the American Glaucoma Society Annual Meeting; 2006 Mar 2-5; Charleston (SC)